
Coherus BioSciences CHRS
$ 0.37
-5.13%
Coherus BioSciences Total Current Liabilities | CHRS
Annual Total Current Liabilities Coherus BioSciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 140 M | 283 M | 332 M | 139 M | 165 M | 146 M | 115 M | 33.3 M | 28.4 M | 56.4 M | 106 M | 51.8 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 332 M | 28.4 M | 133 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Annexon
ANNX
|
42.6 M | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
2.15 M | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
692 K | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
1.1 M | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
2.84 M | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
9.08 M | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
4.56 M | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
7.03 M | - | - | $ 35.3 M | ||
|
Axcella Health
AXLA
|
14.1 M | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
7.76 M | - | - | $ 24.2 M | ||
|
Myovant Sciences Ltd.
MYOV
|
250 M | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
21.4 M | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
42.7 M | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
16.3 M | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
1.32 M | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
6.85 M | - | - | $ 109 M | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
122 M | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
2.74 M | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
49.6 M | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
17.6 M | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
2.47 M | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
9.94 M | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
10.8 M | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
6.63 M | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
82.4 M | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | ||
|
bluebird bio
BLUE
|
321 M | - | - | $ 546 M | ||
|
Landos Biopharma
LABP
|
6.25 M | - | 0.58 % | $ 144 M | ||
|
CASI Pharmaceuticals
CASI
|
17 M | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
20.8 M | - | -5.16 % | $ 5.39 M | ||
|
Sigilon Therapeutics
SGTX
|
31 M | - | - | $ 728 M | ||
|
Regulus Therapeutics
RGLS
|
7.5 M | - | - | $ 155 M | ||
|
NGM Biopharmaceuticals
NGM
|
20.1 M | - | - | $ 127 M | ||
|
Aravive
ARAV
|
22.1 M | - | -13.39 % | $ 1.45 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
85.1 M | $ 84.95 | 0.13 % | $ 7.99 B | ||
|
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | ||
|
Gilead Sciences
GILD
|
11.8 B | $ 166.01 | -0.31 % | $ 207 B | ||
|
Assembly Biosciences
ASMB
|
48.8 M | $ 22.14 | -1.6 % | $ 248 M | ||
|
Dynavax Technologies Corporation
DVAX
|
78.6 M | - | - | $ 2.02 B | ||
|
Turning Point Therapeutics
TPTX
|
47.1 M | - | -0.13 % | $ 3.73 B | ||
|
Orgenesis
ORGS
|
26.9 M | - | -33.86 % | $ 61.2 M | ||
|
TCR2 Therapeutics
TCRR
|
64.1 M | - | - | $ 58.1 M |